登录新浪财经APP 搜索【信披】查看更多考评等级 根据华安基金管理有限公司（以下简称"本公司"）与华鑫证券有限责任公司（以下简称"华鑫证券"）签 署《华安基金管理有限公司交易型开放式指数证券投资基金申购赎回代理协议》，自2026年1月21日 起，将新增华鑫证券为本公司旗下部分基金申购赎回代办证券公司（以下简称"一级交易商"）。投资者 可通过华鑫证券各营业网点办理以下基金的申购、赎回等业务。 ■ 投资者可通过以下渠道咨询详情： （1）华鑫证券有限责任公司 注册地址：深圳市福田区香蜜湖街道东海社区深南大道7888号东海国际中心一期A栋2301A 网址：www.hxrzrq.com （2）华安基金管理有限公司 客户服务电话：40088-50099 公司网址：www.huaan.com.cn 风险提示：本公司承诺以诚实信用、勤勉尽责的原则管理和运用基金资产,但不保证基金一定盈利,也不 保证最低收益。投资者应当认真阅读《基金合同》、《招募说明书》、基金产品资料概要等信息披露文 件。敬请投资者注意投资风险。 特此公告 华安基金管理有限公司 二〇二六年一月二十一日 华安基金管理有限公司 关于旗下部分基金增加国金证券股份有限 ...

Group 1: Power Generation Business - In Q4 2025, the company's consolidated power generation reached 5.461 billion kWh, with grid electricity sales (including photovoltaic sales) at 5.236 billion kWh, representing year-on-year growth of 3.03% and 2.97% respectively [1] - For the full year 2025, the total power generation was 24.376 billion kWh, and grid electricity sales were 23.389 billion kWh, showing year-on-year increases of 1.99% and 2.26% respectively [1] - The company is in the process of decommissioning two 320MW coal-fired units at the Zhujiang Power Plant and replacing them with two 640MW ultra-supercritical coal-fired units, with the first phase expected to be completed by December 31, 2024 [1] Group 2: Natural Gas Business - As of December 31, 2025, the company reported an increase in LNG sales, attributed to growth in both city gas terminal consumption and wholesale gas volumes [3] Group 3: Fuel Business - The company sold 52.02 million tons of coal by December 31, 2025, marking a year-on-year increase of 20.9% [4] Group 4: Overall Strategy and Development - The year 2025 marks the conclusion of the "14th Five-Year Plan," with the company achieving its strategic goals of tripling investment, installed capacity, and natural gas supply by the end of the year, reaching a total installed capacity of 10.97 million kW [5] - The company is expanding its operations from the Guangdong-Hong Kong-Macao Greater Bay Area to 26 provinces and 11 countries, focusing on a transition from clean energy to a green low-carbon model, with 77% of its installed capacity being green low-carbon [5] - The company is shifting its development model from primarily industrial operations to a capital-linked approach, accelerating the development of energy storage and hydrogen energy, and advancing digital projects such as smart power plants and smart gas platforms [5]

Core Viewpoint - The company anticipates a significant decline in financial performance for the year 2025, projecting a net loss attributed to the parent company of between 1.40 billion and 1.20 billion yuan, alongside a decrease in revenue compared to the previous year [2][3]. Financial Performance Forecast - The company estimates that for the fiscal year 2025, it will achieve approximately 383 million yuan in revenue [2][3]. - The projected net loss for the year 2025 is between 1.40 billion and 1.20 billion yuan [2][3]. - The net profit attributable to the parent company, after excluding non-recurring gains and losses, is expected to be between 1.43 billion and 1.23 billion yuan [4]. Previous Year Comparison - In the previous year, the company reported revenue of 401 million yuan [5]. - The net profit attributable to the parent company was 19.38 million yuan, with a net profit of 18.40 million yuan after excluding non-recurring gains and losses [5]. Reasons for Expected Loss - The primary reason for the anticipated loss is a decrease in revenue from the core business of new energy batteries, coupled with a decline in gross margin, leading to a downturn in operational performance [7]. - The company is also facing potential impairment of long-term assets due to the performance forecasts of two subsidiaries in the new energy battery sector [7]. - The company’s associate, Liaoning Shidai Dasha Co., Ltd., is expected to incur losses, which will be recognized as investment losses under the equity method [8]. - There are concerns regarding receivables from the subsidiary Liaoning Jiuyi Lithium Energy Co., Ltd., which has a long-term negative net asset value, indicating a substantial risk of loss on these receivables [8].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 一、交易概述 佳都科技集团股份有限公司（以下简称"公司"）全资子公司广东华之源信息工程有限公司（以下简 称"华之源"）以现金7,920万元收购青岛海信微联信号有限公司（以下简称"海信微联"）60%的股权，分 别受让其现有股东青岛海信网络科技股份有限公司（以下简称"青岛海信"）持有的41%股权、受让其现 有股东北京交大微联科技有限公司（以下简称"交大微联"）持有的19%股权，华之源已与青岛海信、交 大微联完成相关股权转让协议的签署。本次交易完成后，海信微联成为公司持股60%的控股子公司。具 体内容详见公司于2025年12月16日在上海证券交易所网站（www.sse.com.cn）披露的《佳都科技关于收 购青岛海信微联信号有限公司60%股权的公告》（公告编号：2025-095）。 二、本次交易进展情况 近日，海信微联已就上述股权转让事项完成工商变更登记，正式更名为"青岛佳都微联信号系统有限公 司"，并取得青岛市崂山区行政审批服务局换发的新《营业执照》，相关工商登记信息如下： 成 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 青岛英派斯健康科技股份有限公司（以下简称"公司"）近日接到控股股东海南江恒实业投资有限公司 （以下简称"海南江恒"）通知，获悉海南江恒所持有的本公司部分股份被质押，具体事项如下： 一、股东股份质押基本情况 （一）本次股份质押基本情况 ■ 本次质押股份不存在负担重大资产重组等业绩补偿义务。 （二）股东股份累计质押情况 截至公告披露日，海南江恒所持质押股份情况如下： ■ 注：本公告中"持股比例"、"占公司总股本比例"均未剔除公司回购专用账户中的股份数。 二、其他情况说明 截至本公告日，控股股东海南江恒质押的股份不存在平仓或被强制过户的风险，质押风险在可控范围之 内，上述质押行为不会导致公司实际控制权发生变更。如后续出现平仓风险，海南江恒将及时通知公司 披露相应的风险提示，并积极采取相关措施应对平仓风险。公司将持续关注其质押情况及质押风险情 况，并按规定及时做好相关信息披露工作，敬请投资者注意投资风险。 三、备查文件 1、中国证券登记结算有限责任公司出具的《证券质押及司 ...

Transaction Overview - The company has decided to publicly transfer 100% equity of its subsidiary, Hunan Jinshi Technology Co., Ltd., to optimize its asset structure and improve resource utilization efficiency [2] - The initial listing price for the equity was set at 40,502.05 million yuan, with a public announcement period of 15 working days starting from September 10, 2025 [3] Public Listing Progress - As of the end of the public listing period, no suitable buyers were found for the equity, leading the company to initiate a second round of listing with a reduced price of 34,426.74 million yuan [3][4] - The company continued to lower the listing price in subsequent rounds, with the final price set at 17,970.97 million yuan for the next round of listing starting January 20, 2026 [4]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has received clinical trial approval from the National Medical Products Administration for two drugs, SHR-9839 and HRS-4642, indicating progress in its oncology pipeline [1][2]. Group 1: Drug Information - SHR-9839 is a humanized antibody drug developed by the company, intended for the treatment of advanced solid tumors by blocking two key signaling pathways related to tumor development. The total R&D investment for SHR-9839 has reached approximately 93.9 million yuan (about 13.5 million USD) [1]. - HRS-4642 is a KRAS G12D inhibitor in a liposome formulation, specifically designed to bind to KRAS G12D and inhibit the phosphorylation of MEK and ERK proteins, with no similar drugs approved in the market. The cumulative R&D investment for HRS-4642 is approximately 254.2 million yuan (about 36.5 million USD) [2]. - HRS-2141 tablets (I) and (II) have also received clinical trial approval for type 2 diabetes treatment, with a cumulative R&D investment of about 5.4 million yuan (about 0.8 million USD) [6]. Group 2: Regulatory Approval - The company has received the clinical trial approval notice for SHR-9839 and HRS-4642, allowing it to proceed with clinical trials [1][2]. - The approval for HRS-2141 tablets was granted based on compliance with the relevant drug registration requirements, allowing the company to initiate clinical trials for the diabetes indication [6].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 二、离任对公司的影响 根据《中华人民共和国公司法》、《公司章程》等有关规定，张剑兴先生的离任不会导致公司现有董事 会成员人数低于法定最低人数，不会影响公司董事会的正常运行。刘峰先生的离任不会影响公司正常生 产经营。 张剑兴先生、刘峰先生已确认与公司和公司董事会之间无意见分歧，亦无任何需提呈公司股东注意的事 项。 张剑兴先生、刘峰先生在公司任职期间恪尽职守、勤勉尽责、客观公正，为公司规范运作和健康发展发 挥了重要作用，公司及董事会对张剑兴先生、刘峰先生在任职期间所做的贡献表示衷心的感谢！ 特此公告。 近日，上海振华重工（集团）股份有限公司（以下简称公司）董事会收到公司董事张剑兴先生、副总经 理（副总裁）刘峰先生的书面辞呈。现将具体情况公告如下： 一、董事、高级管理人员离任情况 因工作安排，张剑兴先生辞去公司董事、董事会战略委员会委员、董事会薪酬与考核委员会委员职务。 刘峰先生辞去公司副总经理（副总裁）职务。 ■ 根据《上海证券交易所上市公司自律监管指引第 1 号一一规范运作》及《公 ...

Group 1 - The company plans to acquire 51% of Wuxi Yubang Semiconductor Technology Co., Ltd. for a total cash investment of 391.68 million yuan, which will make Yubang Semiconductor a subsidiary included in the company's consolidated financial statements [1][2] - The transaction is in line with national policies encouraging mergers and acquisitions to promote industrial transformation and optimize the company's structure [2][31] - The board of directors approved the acquisition without the need for shareholder approval, and the transaction does not constitute a related party transaction or a major asset restructuring [1][3] Group 2 - Yubang Semiconductor specializes in integrated circuit manufacturing repair equipment, providing comprehensive services including equipment repair, parts supply, and technical support [4][6] - The global repair equipment market is projected to grow from 3.7 billion USD in 2024 to 8.49 billion USD by 2030, with a compound annual growth rate (CAGR) of 13.8% [7] - Yubang Semiconductor's revenue for 2024 and the first nine months of 2025 was 149.79 million yuan and 166.05 million yuan, respectively, with net profits of 13.00 million yuan and 22.18 million yuan, indicating steady growth [7][34] Group 3 - The acquisition is expected to enhance the company's financial position and profitability, with performance commitments from Yubang Semiconductor to achieve net profits of at least 50 million yuan, 53 million yuan, and 56 million yuan for the years 2026, 2027, and 2028, respectively [34][26] - The transaction will allow the company to diversify its business and enter the semiconductor industry, aligning with its long-term strategic goals [32][33] - The company aims to leverage Yubang Semiconductor's technology and customer resources to improve asset quality and overcome existing business development bottlenecks [34][35]

Core Viewpoint - Shanghai Haitong Securities Asset Management Co., Ltd. has announced the termination of the Haitong Quantitative Growth Selected One-Year Holding Mixed Asset Management Plan, which will enter liquidation procedures starting January 1, 2026, due to triggering contract termination conditions [3]. Group 1: Asset Management Plan Details - The Haitong Quantitative Growth Selected One-Year Holding Mixed Asset Management Plan will terminate on December 31, 2025, and will begin liquidation on January 1, 2026 [3]. - The plan holds 107,300 shares of Zhengyuan Co., Ltd. (stock code: 600321), which has been delisted and is now traded on the National Equities Exchange and Quotations system [3]. - The first liquidation period will run from January 1, 2026, to January 16, 2026, with a second liquidation period to be determined based on the timing of asset realization [3]. Group 2: Remaining Asset Distribution - The net assets available for distribution after deducting unrealized assets and accrued interest are RMB 26,267,747.32, with specific allocations for different share classes: A class will receive RMB 9,850,748.16, B class RMB 16,093,021.56, and C class RMB 323,977.60 [4]. - The distribution will occur in cash based on the proportion of shares held by each class on the last operational day of the plan [4]. - Following the completion of the remaining asset distribution, the management will proceed with account cancellation and other related business as per legal regulations [5]. Group 3: Additional Announcements - A liquidation report for the Haitong Quantitative Value Selected One-Year Holding Mixed Asset Management Plan will also be published on January 21, 2026, with the full report available on the company's website and the China Securities Regulatory Commission's electronic disclosure site [7].